vs
Apellis Pharmaceuticals, Inc.（APLS）与EVI INDUSTRIES, INC.（EVI）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是EVI INDUSTRIES, INC.的1.7倍（$199.9M vs $115.3M），EVI INDUSTRIES, INC.净利率更高（2.1% vs -29.5%，领先31.5%），EVI INDUSTRIES, INC.同比增速更快（24.4% vs -5.9%），过去两年EVI INDUSTRIES, INC.的营收复合增速更高（17.2% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
EVI Industries是一家商用洗衣、干洗及衣物护理设备的领先分销商，主要服务北美市场，客户涵盖自助洗衣店、酒店、医疗机构及多户住宅物业，同时提供设备安装、维护及售后支持服务。
APLS vs EVI — 直观对比
营收规模更大
APLS
是对方的1.7倍
$115.3M
营收增速更快
EVI
高出30.3%
-5.9%
净利率更高
EVI
高出31.5%
-29.5%
两年增速更快
EVI
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $115.3M |
| 净利润 | $-59.0M | $2.4M |
| 毛利率 | — | 30.8% |
| 营业利润率 | -25.6% | 3.7% |
| 净利率 | -29.5% | 2.1% |
| 营收同比 | -5.9% | 24.4% |
| 净利润同比 | -62.2% | 109.9% |
| 每股收益（稀释后） | $-0.40 | $0.15 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSEVI
| Q4 25 | $199.9M | $115.3M | ||
| Q3 25 | $458.6M | $108.3M | ||
| Q2 25 | $178.5M | $110.0M | ||
| Q1 25 | $166.8M | $93.5M | ||
| Q4 24 | $212.5M | $92.7M | ||
| Q3 24 | $196.8M | $93.6M | ||
| Q2 24 | $199.7M | $90.1M | ||
| Q1 24 | $172.3M | $84.0M |
净利润APLSEVI
| Q4 25 | $-59.0M | $2.4M | ||
| Q3 25 | $215.7M | $1.8M | ||
| Q2 25 | $-42.2M | $2.1M | ||
| Q1 25 | $-92.2M | $1.0M | ||
| Q4 24 | $-36.4M | $1.1M | ||
| Q3 24 | $-57.4M | $3.2M | ||
| Q2 24 | $-37.7M | $2.1M | ||
| Q1 24 | $-66.4M | $956.0K |
毛利率APLSEVI
| Q4 25 | — | 30.8% | ||
| Q3 25 | — | 31.3% | ||
| Q2 25 | — | 30.8% | ||
| Q1 25 | — | 30.0% | ||
| Q4 24 | — | 29.7% | ||
| Q3 24 | — | 30.8% | ||
| Q2 24 | — | 30.4% | ||
| Q1 24 | — | 30.7% |
营业利润率APLSEVI
| Q4 25 | -25.6% | 3.7% | ||
| Q3 25 | 48.7% | 3.3% | ||
| Q2 25 | -18.6% | 3.7% | ||
| Q1 25 | -50.0% | 2.4% | ||
| Q4 24 | -12.3% | 2.6% | ||
| Q3 24 | -24.0% | 5.3% | ||
| Q2 24 | -14.7% | 4.1% | ||
| Q1 24 | -36.0% | 2.9% |
净利率APLSEVI
| Q4 25 | -29.5% | 2.1% | ||
| Q3 25 | 47.0% | 1.7% | ||
| Q2 25 | -23.6% | 1.9% | ||
| Q1 25 | -55.3% | 1.1% | ||
| Q4 24 | -17.1% | 1.2% | ||
| Q3 24 | -29.2% | 3.5% | ||
| Q2 24 | -18.9% | 2.3% | ||
| Q1 24 | -38.5% | 1.1% |
每股收益（稀释后）APLSEVI
| Q4 25 | $-0.40 | $0.15 | ||
| Q3 25 | $1.67 | $0.11 | ||
| Q2 25 | $-0.33 | $0.14 | ||
| Q1 25 | $-0.74 | $0.07 | ||
| Q4 24 | $-0.30 | $0.07 | ||
| Q3 24 | $-0.46 | $0.21 | ||
| Q2 24 | $-0.30 | $0.13 | ||
| Q1 24 | $-0.54 | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $144.0M |
| 总资产 | $1.1B | $315.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSEVI
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | $4.7M | ||
| Q2 25 | $370.0M | $8.9M | ||
| Q1 25 | $358.4M | $5.9M | ||
| Q4 24 | $411.3M | $3.9M | ||
| Q3 24 | $396.9M | $4.4M | ||
| Q2 24 | $360.1M | $4.6M | ||
| Q1 24 | $325.9M | $3.3M |
总债务APLSEVI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $24.0M | ||
| Q4 24 | — | $27.9M | ||
| Q3 24 | — | $19.9M | ||
| Q2 24 | — | $12.9M | ||
| Q1 24 | $93.1M | $21.9M |
股东权益APLSEVI
| Q4 25 | $370.1M | $144.0M | ||
| Q3 25 | $401.2M | $140.8M | ||
| Q2 25 | $156.3M | $143.5M | ||
| Q1 25 | $164.2M | $140.2M | ||
| Q4 24 | $228.5M | $138.0M | ||
| Q3 24 | $237.1M | $136.1M | ||
| Q2 24 | $264.3M | $136.6M | ||
| Q1 24 | $266.7M | $133.5M |
总资产APLSEVI
| Q4 25 | $1.1B | $315.6M | ||
| Q3 25 | $1.1B | $321.8M | ||
| Q2 25 | $821.4M | $307.0M | ||
| Q1 25 | $807.3M | $251.8M | ||
| Q4 24 | $885.1M | $248.8M | ||
| Q3 24 | $901.9M | $245.5M | ||
| Q2 24 | $904.5M | $230.7M | ||
| Q1 24 | $831.9M | $239.3M |
负债/权益比APLSEVI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.17× | ||
| Q4 24 | — | 0.20× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | 0.09× | ||
| Q1 24 | 0.35× | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $4.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | 1.70× |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSEVI
| Q4 25 | $-14.2M | $4.0M | ||
| Q3 25 | $108.5M | $1.0M | ||
| Q2 25 | $4.4M | $9.9M | ||
| Q1 25 | $-53.4M | $9.1M | ||
| Q4 24 | $19.4M | $2.0M | ||
| Q3 24 | $34.1M | $207.0K | ||
| Q2 24 | $-8.3M | $12.4M | ||
| Q1 24 | $-133.0M | $9.4M |
自由现金流APLSEVI
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | $-890.0K | ||
| Q2 25 | $4.4M | $8.2M | ||
| Q1 25 | $-53.4M | $8.1M | ||
| Q4 24 | $19.3M | $1.1M | ||
| Q3 24 | — | $-1.0M | ||
| Q2 24 | $-8.4M | $11.2M | ||
| Q1 24 | $-133.3M | $8.1M |
自由现金流率APLSEVI
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | -0.8% | ||
| Q2 25 | 2.5% | 7.5% | ||
| Q1 25 | -32.0% | 8.7% | ||
| Q4 24 | 9.1% | 1.2% | ||
| Q3 24 | — | -1.1% | ||
| Q2 24 | -4.2% | 12.4% | ||
| Q1 24 | -77.3% | 9.7% |
资本支出强度APLSEVI
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | 1.8% | ||
| Q2 25 | 0.0% | 1.5% | ||
| Q1 25 | 0.0% | 1.1% | ||
| Q4 24 | 0.0% | 0.9% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.0% | 1.3% | ||
| Q1 24 | 0.2% | 1.5% |
现金转化率APLSEVI
| Q4 25 | — | 1.70× | ||
| Q3 25 | 0.50× | 0.55× | ||
| Q2 25 | — | 4.74× | ||
| Q1 25 | — | 8.79× | ||
| Q4 24 | — | 1.74× | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | 5.99× | ||
| Q1 24 | — | 9.85× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
EVI
暂无分部数据
